Long-term systemic and mucosal SARS-CoV-2 IgA response and its association with persistent smell
 and taste disorders.

Jessica Denis¹, Annabelle Garnier¹, Laurence Cheutin¹, Audrey Ferrier¹, Hawa Timera¹, Fanny
 Jarjaval¹, Carine Hejl^{2,3}, Emmanuelle Billon-Denis^{1,6}, Percy ImmunoCovid group, Damien Ricard^{2,3,4},

5 Jean-Nicolas Tournier ^{1,3,6}, Aurélie Trignol ^{1,5,*}, Marie Mura ^{1,6,*}.

6

- 7 1. Institut de Recherche Biomédicale de Armées, 1 place du général Valérie André, 91223 Brétigny 8 sur-Orge, France
- 9 2. Hôpital d'Instruction des Armées Percy, 101 avenue Henri Barbusse, 92140 Clamart, France
- 10 3. Ecole du Val-de-Grâce, 1 place Alphonse Laveran, 75005 Paris, France

11 4. Centre Borelli UMR 9010/Université Paris-Saclay, ENS Paris-Saclay, CNRS, SSA, Université de Paris

- 12 Cité, INSERM ; 4, avenue des Sciences, 91190 Gif-sur-Yvette, France
- 5. Université Paris Cité, VIFASOM (UPR 7330 Vigilance Fatigue, Sommeil et Santé Publique), Paris,
 France
- 15 6. Institut Pasteur, Innovation lab: vaccines, 25-28 rue du Dr Roux, 75015 Paris, France
- 16 * Corresponding authors: <u>marie.mura@def.gouv.fr</u> and <u>aurelie.trignol@def.gouv.fr</u>, 1 place du
- 17 général Valérie André, 91223 Brétigny-sur-Orge, France, +33178651068 and +33178651279.

18

Percy ImmunoCovid group: Guillaume Andéol¹, Arnaud Avril¹, Céline Bonnet², Olivier Ferraris¹,
Vincent Foissaud², Olivier Gorgé¹, Fréderic Iseni¹, Francis Klotz², Lionel Koch¹, Christine Leclere²,
Kelly Meneyrol¹, Mona Michaud^{2,4}, Céline Mizoule², Albane Moreau^{2,4}, Bruno Pats², Diane
Riccobono¹, Clémence Rougeaux¹, Patrick Sandor³, Brian Tervil⁴, Emilie Tessier¹, Anthony Vacher¹,
Philippe Vest², Clarisse Vigne¹, Yordanka Yordanova².

24

1. Institut de Recherche Biomédicale de Armées, 1 place du Général Valérie André, 91223 Brétigny sur-Orge, France.

27 2. Hôpital d'Instruction des Armées Percy, 101 avenue Henri Barbusse, 92140 Clamart, France.

3. Direction de la médecine des forces, 60 boulevard du Général Martial Valin, 75509 Paris Cedex 15,
France.

- 30 4. Centre Borelli UMR 9010/Université Paris-Saclay, ENS Paris-Saclay, CNRS, SSA, Université de Paris
- 31 Cité, INSERM ; 4, avenue des Sciences, 91190 Gif-sur-Yvette, France.

32 Abstract

33 Current approved COVID-19 vaccines, notably mRNA and adenoviral vectored technologies, still fail 34 to fully protect against infection and transmission of various SARS-CoV-2 variants. The mucosal 35 immunity at the upper respiratory tract represents the first line of defense against respiratory viruses 36 such as SARS-CoV-2 and is thus critical to develop vaccine blocking human-to-human transmission. 37 We measured systemic and mucosal Immunoglobulin A (IgA) response in serum and saliva from 133 38 healthcare workers from Percy teaching military hospital following a mild infection (SARS-CoV-2 39 Wuhan strain, n=58) or not infected (n=75), and after SARS-CoV-2 vaccination 40 (Vaxzevria®/Astrazeneca and/or Comirnaty®/Pfizer). While serum anti-SARS-CoV-2 Spike IgA 41 response lasted up to 16 months post-infection, IgA response in saliva had mostly fallen to baseline 42 level at 6 months post-infection. Vaccination could reactivate the mucosal response generated by 43 prior infection, but failed to induce a significant mucosal IgA response by itself. As breakthrough 44 infections have been correlated with IgA levels, other vaccine platforms inducing a better mucosal 45 immunity are needed to control COVID-19 infection in the future. Early post-COVID-19 serum anti-46 Spike-NTD IgA titer correlated with seroneutralization titers. Interestingly, its saliva counterpart 47 positively correlated with persistent smell and taste disorders more than one year after mild COVID-19, and could potentially be used as an early prognosis biomarker. 48

49

50 Key words: mucosal immunity, SARS-CoV-2 vaccine, dysosmia, dysgeusia, Ig A, Spike N-terminal

51 domain

52 **1.** Introduction

53 Protection against infection and mitigation of human-to-human transmission are key factors to block 54 the spread of respiratory viruses, like influenza virus and SARS-CoV-2 (1, 2). These goals designed by 55 herd immunity have not yet been met by current SARS-CoV-2 approved vaccines (3, 4). Systemic 56 vaccination by mRNA and adenovirus-vectored vaccines has shown a great potential in crisis 57 management but fails to induce a prolonged protection against infection and human-to-human 58 transmission by the subsequent variants (5), even though they could reduce the period of 59 transmission by a faster control of viral replication (6). There is a need for second generation vaccines 60 that may broaden the immune response against multiple variants, induce a long-lasting memory 61 response and protect more efficiently against transmission and breakthrough infections, ideally by 62 imprinting a strong mucosal immune response in the upper respiratory tract, as described in recent 63 preclinical studies (7-9).

64 The protection of the respiratory tract is particularly complex since it is provided by the integrity of 65 the epithelial barriers, a protective mucus layer propelled by cilia, antimicrobial peptides and innate 66 immune cells as well as by an adaptive immune response initiated at the inductive sites of 67 nasopharynx-associated-lymphoid tissue (NALT) (10). The local microbiota has also been described as 68 a modulator of the immune response (11). Polymeric immunoglobulins A (IgA) are specific soluble 69 mediators of the adaptive immune response. While IgA are monomeric in human serum, they are 70 produced locally mostly under dimeric form in mucosal tissues and are released with the secretory 71 component at the mucosal lumen as secretory IgA (SIgA). Monomeric Ig are also present in mucosal 72 secretions following passive transport from blood compartment, with a majority of IgG and fewer IgA 73 (12). Natural polyreactive IgA with cross-reactivity and low affinity have also been described in the 74 lumen of mucosal surfaces (13). In contrast to nasal or bronchoalveolar samples, saliva is an easy-to-75 access biofluid where specific SARS-CoV-2 IgA have been detected (14-16), providing information 76 about the mucosal response by harboring a significant population of IgA-secreting plasma cells.

77 Another major health issue of the COVID-19 pandemic is the persistence of long-lasting clinical 78 disorders (so-called long COVID or post-acute sequelae of COVID-19) for a substantial proportion of 79 SARS-CoV-2-infected people, with heterogeneity due to geographic location, SARS-CoV-2 variants 80 and studied population(17, 18). The clinical presentation is highly diverse, involving several organs 81 and systems. Smell and taste disorders were particularly frequent since the initial phase of the 82 COVID-19 pandemic (19, 20), with quantitative (hypo-, hyper-, anosmia or ageusia) or qualitative 83 (dys-, phantosmia or phantageusia) alterations. Persistent olfactory disorders have been notified 84 from 10% to more than 50% according to SARS-CoV-2 variants (18, 19), and can be recovered in a few 85 months. Nevertheless, recent data described less than 40% people with a complete recovery after 2 86 years, and 7.5% displaying no improvement (21). The pathophysiology of long COVID remains poorly 87 understood and may include viral persistence or delayed clearance, autoimmunity and tissue 88 damages due to inflammation. Recent studies have also highlighted the persistence of the humoral 89 response (22, 23). The contribution of the mucosal humoral compartment has started to be 90 investigated to potentially identify prognosis markers (24).

91 In this study, we therefore examined the anti-SARS-CoV-2 IgA response over more than one-year in serum and saliva from a cohort of 133 healthcare workers suffering from a mild COVID-19 (SARS-92 93 CoV-2 Wuhan strain, n=58, the COVID+ group), and non-infected controls (n=75, the COVID- group). 94 We analyzed the antigen specificity of the response against the spike immune-dominant target and 95 its subdomains (Spike (S), Spike receptor binding domain (RBD), Spike N terminal domain (NTD)) and 96 the nucleoprotein (N). We evaluated the impact of pre-exposure to other human coronaviruses 97 (HCoV-NL63, HCoV-229E, HCoV-OC43, HCoV-HKU1) and the reactivation of mucosal immunity after 98 systemic intramuscular vaccination. Post-infection anti-SARS-CoV-2 Spike IgA response in serum was 99 sustained up to 16 months, whereas IgA response in saliva was back to its baseline level after 6 100 months. We observed that vaccination reactivated prior mucosal immune response generated by

infection, while vaccine alone failed to induce significant IgA titers in saliva. Finally, the initial levels
 of serum anti-Spike N-terminal domain (NTD) IgA were found to positively correlate with
 seroneutralization efficacy, whereas their salivary counterpart positively correlated with the
 persistence of smell disorders or taste disorders more than one year after acute COVID-19.

105 **2. Results**

106 **2.1.** Serum anti-SARS-CoV-2 IgA were maintained for up to 16 months post-infection and NTD-107 specificity positively correlated with seroneutralization titers.

108 The main characteristics of the cohort are represented in Table 1. In the total of 400 volunteers 109 achieving the totality of the longitudinal follow-up, we selected 133 individuals (75 naive individuals 110 and 58 previously-infected individuals), based on the certainty of the diagnosis at enrollment, the 111 absence of a new COVID-19 infection during the longitudinal follow-up, and the quality/quantity of 112 saliva samples (Supplementary method and supplementary figure S1).

113 At enrollment (Visit 1 - V1), the median onset of symptoms was 1.5 months (Table 1) and specific 114 anti-SARS-CoV-2 Spike IgA were present in the serum from almost all previously infected individuals 115 (n=56/58) (Figure 1A). The positive threshold of each test was determined by the Youden index (ROC 116 curves in supplementary figure S2). The IgA antibodies targeted preferentially the Spike/RBD 117 (n=54/58) (Figure 1B) than the Spike/NTD (n=48/58) (Figure 1C), and the nucleocapsid-N (n=48/58) (Figure 1D). Six months later (Visit 2 - V2), the IgA signal significantly decreased, regardless of the 118 targeted antigen, as compared to V1 (p<0,001) (Figure 1). Especially, the mean titer of anti-N IgA fell 119 120 under the positive threshold at 6 months. Hypothesizing a linear evolution of the log(IgA signal) over 121 time between V1 and V2, the modeling using linear mixed models found negative slopes 122 (Supplementary Table S1) that corresponded to a daily decrease of IgA concentration of 2.70 % for S, 123 2.78 ‰ for Spike/RBD, 3.95 ‰ for Spike/NTD and 6.52 ‰ for N. Between 6 and 12 months following 124 the inclusion (V2 and V3 respectively), anti-N IgA had a tendency to decrease (Figure 1D), with a 125 negative modeling slope corresponding to a daily decrease of 0.21 ‰, whereas we observed a 126 stabilization of IgA titers against all other targets. The general anti-SARS-CoV-2 serological response 127 (anti-N and anti-Spike/RBD total Ig and seroneutralization titers) from previously infected individuals 128 is shown in figure 2. The Spike/RBD total Ig response (Figure 2A) increased over time (p<0.001), 129 whereas the anti-N total Ig response (Figure 2B) decreased (p<0.001). The seroneutralization capacity 130 of the serum against the BetaCoV/France/IDF0372/2020 strain was maintained up to 16 months 131 post-infection (Figure 2C).

Seroneutralization titers at V1 positively correlated with serum anti-Spike/NTD IgA (Spearman, rho=0.32, p=0.012) (Supplementary figure S3A). More than 6 months post-infection (V2), seroneutralization titers correlated with serum anti-Spike/NTD IgA (Spearman, rho=0.5, p=0.013) and anti-Spike IgA (Spearman, rho=0.32, p=0.03) (Supplementary figure S3B). More than one year after COVID-19 infection (V3) and without any vaccination, seroneutralization titers still correlated with serum anti-Spike IgA (Spearman, rho=0.3, p=0.02) (Supplementary figure S3C).

Overall, we observed in our cohort an induction of high serological titers of anti-SARS-CoV-2 Spike
 IgA that positively correlated with seroneutralization titers, and maintained for up to 16 months
 post-infection despite a first decline after 6 months.

141 2.2. COVID-19 induced weak but significant salivary anti-Spike IgA, followed by a constant decrease 142 over time.

143 At enrollment (V1), specific anti-SARS-CoV-2 IgA were also detected in saliva from infected 144 individuals, as compared to controls individuals (Figure 3). These antibodies targeted the total Spike 145 (p<0.001, figure 3A), preferentially Spike/RBD (p=0.002, figure 3B) than Spike/NTD (p=0.001, figure 146 3C), but not the nucleocapsid (p=0.43, figure 3D). During the first six months, the IgA level in saliva 147 significantly decreased against all targets (p<0,04). The modelling using linear mixed models found 148 negative slopes that corresponded to a daily decrease of IgA concentration of 1.16 % for S, 0.89 %149 for Spike/RBD and 0.90 ‰ for Spike/NTD. Between 6 and 12 months, a similar decrease was 150 observed against these targets (supplementary Table S1).

151 So, a specific anti-SARS-CoV-2 Spike salivary IgA response was noted shortly after infection, but weak,

variable and with a continuous decrease over the time. This was in contrast with anti-N antibodies

153 for which the detected signal did not differ between naive and previously infected individuals.

2.3. Post-COVID19 anti-SARS-CoV-2 Spike IgA titers reached other human coronaviruses range in saliva and serum.

156 In order to evaluate the impact of human coronaviruses pre-exposure on the level of anti-SARS-CoV-157 2 response and estimate the cross-reactivity in vitro, we quantified IgA in serum and saliva against 158 the Spike protein from two alpha-coronaviruses (hCoV-229E, hCoV-NL63) and three beta-159 coronaviruses (hCoV-OC43, hCoV-HKU1, SARS-CoV-1) at V1. No previous exposure to SARS-CoV-1 160 was reported by any participant of the cohort. First, we observed in the COVID-19-negative group a 161 similar range of detected signal against the four hCoV, with slightly higher responses against hCoV-162 OC43 and hCoV-229E compared to hCoV-NL63 and hCoV-HKU1 in serum and saliva (Figure 4A). IgA 163 directed against SARS-CoV-1 or SARS-CoV-2 were weakly detected, which was obvious in the absence 164 of exposure to the viruses in this group and may reflect non-specific response/background noise, or 165 low level of *in vitro* cross-reactivity between human coronaviruses.

166 At V1, there were significantly higher signals against hCoV-HKU1 in the saliva (p=0.04) and SARS-CoV-167 1 in the serum (p<0.001) in the COVID-19+ group than in the COVID-19-negative group. The rest of 168 the signals were unchanged by the COVID-19 status. As these viruses are two beta-coronaviruses 169 belonging to a closer specie, it may be explained by some cross-reactivity in vitro. The detected signal 170 against SARS-CoV-2 Spike after infection in this group reached the same level of response observed 171 against the other hCoV in serum and saliva. Then we looked for correlations between individual responses and noticed that in serum (Figure 4B, right panel, Spearman; supplementary figure S4, 172 173 Pearson) beta-coronaviruses responses correlated together, as well as alpha-coronaviruses, 174 independently of SARS-CoV-2 response. In saliva, the pattern showed a larger correlation between 175 coronaviruses genera (Figure 4B, left panel, Spearman; supplementary figure S5, Pearson).

176 Thus, we identified some cross-reactivity *in vitro* of anti-SARS-CoV-2 Spike IgA against different 177 human coronaviruses. But this phenomenon did not interfere with specific SARS-CoV-2 IgA response 178 that reached the same range of hCoV IgA titers after infection.

179 2.4. Vaccination reactivated mucosal immunity in previously infected individuals but was not able 180 to induce significant mucosal response in naive individuals.

181 At 12 months of the follow-up, the vaccination campaign had already started for healthcare workers, 182 which were a priority population. The vaccine campaign started at the end of December 2020 and a 183 high proportion of the cohort already got vaccinated. At V3, individuals ranged from 0 to 2 doses of 184 vaccine (Table 2) due to limited supplies, updating of vaccine recommendations and vaccine 185 hesitancy. Two vaccination schedules were conducted at this time (Table 3), with 54 individuals 186 having received first an mRNA vaccine (Pfizer-BioNTech, Comirnaty®) and 32 individuals having 187 received first a ChAd-vectored vaccine (Astrazeneca, Vaxzevria®). Few people (n=14) received a 188 heterologous prime-boost with Vaxzevria® followed by Comirnaty® 12 weeks apart (as compared to 4 189 weeks apart for 2 doses of Comirnaty®). The remaining vaccinated individuals got two doses of 190 Comirnaty[®] (n=37). At V3 and without vaccination, previously infected individuals did not have any 191 more detectable circulating anti-N IgA whereas anti-Spike (including Spike/RBD and Spike/NTD) IgA 192 were still present. Both vaccination schedule induced significant titers of anti-SARS-CoV-2 Spike IgA in 193 serum (Supplementary Figure S6), in naive and in previously infected individuals. The different group 194 comparisons with the level of significance are represented in Figure 5. Not surprisingly, the specificity 195 of the response was restricted to the Spike, including Spike/RBD and Spike/NTD, and did not extend 196 to the nucleocapsid, an antigen absent from all vaccines. Nevertheless, even after 2 doses, IgA levels 197 in the serum from COVID-19-negative individuals did not reach the level of response observed in 198 previously infected individuals after one or two doses (p<0.001).

199 In saliva, we observed significantly higher titers of anti-Spike IgA in individuals previously infected by 200 COVID-19 after one dose (p=0.02) or two doses (p=0.003) of vaccine (Figure 6A). It seemed to have 201 no difference between both vaccination schedules (Supplementary figure S7), when taking into 202 account the variability of the delay between the last vaccine dose and the visit, but we did not have a 203 sufficient number of subjects to statistically confirm it. Conversely, the vaccine alone in naive 204 individuals (one or two doses) did not induce specific salivary anti-Spike IgA. Similar results were 205 observed for SARS-CoV-2 Spike/RBD (Figure 6B) and Spike/NTD-specific IgA (Figure 6C). The anti-206 Spike IgA signals in the COVID-19-positive group after vaccination (one dose, V3) were highly 207 correlated with the V1 post-COVID-19 response (Adj R^2 =0.735, p<0.001) (Figure 7A). Moreover, the 208 slope of the linear regression between serum and saliva after immunization (one or two doses) was 209 highly different in naive (Adj R^2 =0.31, slope = 1, p<0.001) and previously infected individuals (Adj 210 R^2 =0.44, slope = 0.45, p<0.001) (Figure 7B). These analyses were not affected by the removal of two 211 individuals with extremely high IgA levels in saliva and serum (data not shown), and supported the 212 hypothesis that immunization reactivated previously-induced mucosal immunity.

213 After vaccination, seroneutralization titers (Supplementary figure S8 and S3D) highly correlated with 214 serum anti-Spike/NTD IgA level (Spearman, rho=0.92, p=0.0001), saliva anti-Spike/NTD IgA level 215 (Spearman, rho=0.84, p=0.003), serum anti-Spike IgA (rho=0.86, p=0.0001) and with a lower 216 correlation with serum anti-Spike/RBD IgA (Spearman, rho=0.36, p=0.005). The post-vaccine titers of 217 anti-SARS-CoV-2 Spike IgA in serum and saliva did not modify the initial level of anti-NL63 and 229E 218 hCoV Spike IgA signals (supplementary figure S9 and S10), but highly increased anti-SARS-CoV-1 Spike 219 signal and slightly anti-OC43 and HKU1 anti-Spike signals (beta-coronaviruses) in serum, confirming 220 that the correlation between human coronaviruses may interfere with the serodiagnosis shortly after 221 vaccination.

Altogether, these results highly suggested that vaccination with mRNA and ChAd-vectored vaccines reactivated mucosal immunity in previously infected COVID-19 individuals but was not sufficient to induce an effective mucosal response in naive individuals.

225 **2.5.** Anti-SARS-CoV-2 Spike/NTD IgA titers induced by COVID-19 are significantly higher in 226 individuals suffering from persistent smell or taste disorders one year after the acute infection.

227 During the longitudinal follow-up of the cohort, the clinical status was evaluated at each visit. An 228 important proportion of COVID-19 infected individuals had a significant persistence of symptoms 229 after one year (43.5%), especially taste disorders, including dys-, hypo- and ageusia (n=38/102 in the 230 cohort, n=10/58 in our study) and smell disorders, including dys-, hypo- and anosmia (n=42/102 in 231 the cohort, n=13/58 in our study) (Supplementary Figure S11). We compared anti-SARS-CoV-2 IgA 232 response in serum and saliva after infection from individuals with smell (Figure 8A) or taste disorders 233 (Figure 8B) persisting less or more than one year after the acute infection with SARS-CoV2 ancestor 234 Wuhan strain. We found out that patients with smell and taste disorders persisting more than one 235 year had higher titers of anti-SARS-CoV-2 IgA in saliva at enrollment (V1), significantly targeting the 236 Spike/NTD (taste disorders, p=0.02; taste disorders, p=0.04) but not in serum. As Spike-NTD 237 specificity was positively correlated with higher seroneutralization titers, it suggests that it could be 238 an IgA target of clinical relevance.

239 3. Discussion

240 We followed SARS-CoV-2 IgA response in serum and saliva one year after a COVID-19 outbreak 241 (SARS-CoV-2 Wuhan strain) in healthcare workers. By exploring its antigen specificity and kinetics, we 242 aimed at better understanding the induction and persistence of mucosal immunity after infection 243 and vaccination. We showed different kinetics and level of anti-Spike IgA in serum and saliva after 244 infection, the first being sustainable up to 16 months after a first decline, the second being lost after 245 6 months. The antigen specificity of anti SARS-CoV-2 IgA unveiled the Spike/NTD as an important 246 target, with positive correlations between serum anti-Spike/NTD IgA and titers of neutralizing 247 antibodies, and saliva initial anti-Spike/NTD IgA levels and long-term persistence of smell and taste 248 disorders. Vaccination with mRNA or Adenovirus-vectored vaccines reactivated a mucosal response 249 in previously infected individuals but failed to induce a significant mucosal response in naive 250 individuals, as already observed on a more limited cohort (25). As breakthrough infections have been 251 correlated with IgA levels (16), IgA production may be a key point to address the issue of controlling 252 the infection locally and preventing the transmission from vaccinated individuals. Most efficient 253 vaccine platforms or route of administration inducing mucosal immunity are needed in the future for 254 COVID-19 control, as already shown in preclinical studies (7, 9).

255 We used saliva IgA as a surrogate marker of mucosal immunity (10). Indeed, two major antibody 256 classes operate in this fluid: secretory IgA and IgG. Most IgG in saliva are derived from serum 257 whereas IgA are mostly synthesized by plasma cells in salivary glands, reflecting a local immune 258 response that is generated independently from systemic IgA (12, 26). Saliva constitutes an interesting 259 fluid offering an insight into the mucosal immune response (27), and a window into the plasma due to vascular leakage from the gingival crevicular epithelium (28, 29). Saliva is easier to sample and 260 261 more accepted than nasal swab or nasal epithelial lining fluid. Previous studies on respiratory viruses, 262 like influenza virus have already confirmed that saliva is good proxy at deciphering mucosal immunity 263 (30-32).

264 The kinetics and antigen specificity of anti-SARS-CoV-2 IgA in our study underlined the sustainability 265 of anti-Spike IgA response in serum over 16 months, after a first decline. This sustainability of the IgA 266 response has already been described over 115 days post-infection with a rapid decline of IgA and IgM 267 responses after a peak at days 16-30 (15), and for up to 8 months (33) and one year (34, 35). We 268 were not able to catch the peak response in our cohort but we confirmed the decline between 269 enrollment (early time post-onset of symptoms) and 6 months later, and the stability between 6 and 270 12 months. Early SARS-CoV-2 humoral response were shown to be dominated by IgA antibodies that 271 contributed greatly to virus neutralization, in serum and saliva (36). By studying the antigen-272 specificity of the Spike response, we identified Spike/NTD as a specific IgA target that correlated with seroneutralization titers. A shift of the humoral response toward the Spike/NTD domain had 273 274 previously been described after the second boost, despite the fact that some Omicron sublineages 275 displayed several NTD mutations (37). Monoclonal antibodies targeting the Spike/NTD have shown in 276 previous studies their ability to inhibit cell-to-cell fusion, to activate effector functions and to protect 277 Syrian hamsters from SARS-CoV-2 challenge (38). Although, serum IgA titers have been correlated 278 with the severity of the disease (39, 40). In our cohort of healthcare workers, the acute symptoms 279 were mainly mild and could not been associated with the anti-Spike/NTD IgA titers. In saliva, IgA 280 mainly targeted the Spike protein (including RBD and NTD specificity), with low titers constantly 281 declining over the year of the follow-up. In previous studies, salivary IgG in mild-COVID-19 were 282 detectable for up to 9 months post-recovery, whereas salivary IgA were short-lived. But salivary 283 dimeric IgA were 15 times more potent than IgA monomers in a pseudoneutralization assay (41).

In our cohort, we observed slightly higher serum IgA titers against hCoV-229E and hCoV-0C43 than hCoV-NL63 and hCoV-HKU1. This description was similarly observed in another cohort using a beadbased multiplexed assay (42) and may reflect previous exposure in the life to these different circulating human coronaviruses (hCoVs). We noticed cross-reactivity inside hCoVs genera in serum,

and more broadly between genera in saliva. Cross-reactive antibodies to hCoVs have been already reported in serum, against beta-hCoVs preferentially (43). The differences observed between correlations in serum and saliva were not surprising, as salivary IgA are generated locally and independently of systemic IgA. Mucosal immunity could favor the acquisition of a broader antigenic specificity than systemic immunity. We showed after infection that the level of anti-SARS-CoV-2 IgA response reached the range observed for the other hCoVs.

294 After vaccination, we confirmed that previously infected individuals had higher titers of IgA in serum 295 than naive individuals and only naive people benefited from a booster effect of the second dose (44-296 46). Notably, even after two doses, IgA titers from naive individuals did not reach the level of 297 response of previously infected individuals. In our cohort, only anti-Spike/NTD IgA specificity in 298 serum was associated with neutralizing antibodies after infection. After vaccination, Spike, 299 Spike/NTD and Spike/RBD positively correlated with neutralizing antibodies, as observed in other 300 cohorts (45), but we also noticed a positive correlation with Spike/NTD in saliva. In previous studies, 301 a detectable neutralizing activity in saliva observed 2 to 4 weeks post-vaccination was described low 302 and transient with a rapid decline (16, 47). The ratio of saliva/serum IgA clearly showed two 303 differential profiles according to previous COVID-19 status. Salivary IgA were not induced after 304 vaccination in naive individuals. Conversely, salivary IgA were highly reactivated after vaccination in 305 individuals previously exposed to SARS-CoV-2, and did not mirror serum IgA, suggesting that systemic 306 vaccination could reactivate previously acquired mucosal immunity. This observation emphasized the 307 importance of the first encounter of the antigen that imprints the immune response. Immune 308 imprinting is a phenomenon whereby initial exposure to an antigen effectively primes lymphocyte 309 memory to determine the eventual destination of an activated T cell, and the generation of local 310 tissue-immunity, but limits the development of a different pattern of response that would be 311 necessary to protect against a variant or another strain of the same pathogen after a secondary 312 encounter of the antigen. It is known for viruses like influenza that the mode of initial exposure to a 313 virus or a vaccine affects both the strength of the response and the breadth of the imprint (48, 49).

314 Lastly, we noticed that individuals suffering from persistent taste or smell disorders more than one 315 year after a mild COVID-19 had higher initial titers of saliva anti-SARS-CoV-2 IgA targeting more 316 specifically the Spike/NTD than individuals who recovered before one year. After vaccination, there 317 was no more difference between the 2 groups. Persisting olfactory and gustatory dysfunctions were 318 commonly reported, and probably underestimated (50). We could not correlate the level of the 319 Spike/NTD-specific antibody response with the initial viral load as the outbreak took place very early, 320 in March 2020, before semi-quantitative molecular diagnosis tools were deployed at our hospital. 321 Studies in animals associated these symptoms with viral persistence and inflammation in the 322 olfactory epithelium (51), but the underlying mechanisms of these persistent dysfunctions are still 323 debated (19). Recent studies have started to explore the involvement of humoral responses in 324 systemic (52, 53) and mucosal compartments (24). In accordance with their results, we did not 325 observe a major difference in serum IgA regarding the duration of olfactory symptoms. Saussez et al. 326 showed that persistent olfactory outcomes at 2 months were associated with lower saliva and nasal 327 IgG1, without any modification of mucosal IgA (24). However, they did not investigate the level of 328 specific anti-Spike/NTD IgA. Our observation was done on few subjects and needs to be confirmed in 329 other cohorts. If confirmed, further studies will be needed to explore the underlying mechanism. It 330 would also help physicians to predict the outcome of smell and taste disorders in order to address 331 rapidly individuals at risk to otorhinolaryngology specialists.

332 **4. Material and methods**

333 4.1. Ethical statements

Ethical approval of the cohort study "Immuno-Covid Percy" was given by the Committee for Protection of Persons engaged in clinical research (CPP 20.05.25) and was registered in clinicaltrials.gov (NCT04408001). A written consent was obtained from all participants prior enrollment. The participants did not receive any compensation. Blood and saliva samples were anonymized, handled aliquoted and stored at appropriate temperature (-20°C for the saliva and the serum after blood centrifugation).

340 **4.2. Cohort follow-up**

341 The cohort follow-up started after a major outbreak among healthcare workers at the military 342 teaching hospital Percy (HIA Percy) at the end of February 2020. The study population was 343 constituted of hospital workers, including caregivers but also administrative staff. Subjects with a 344 severe form of COVID-19 or immune disorders were excluded. At the initial visit (V1, from day 8 to 345 day 118 after the onset of symptoms), volunteers were included, examined and followed at 6 months 346 (V2, from day 193 to 305 post-onset of symptoms) and 12 months later (V3, from day 375 to day 479 347 post-onset of symptoms, ie. up to 16 months after infection). At each consultation, blood and saliva 348 were sampled and the volunteers completed a medical form (Supplementary method). 349 Convalescents (COVID+ group) and uninfected individuals (COVID- group) were defined on their 350 SARS-CoV-2 genome detection (PCR) and/or total immunoglobulin serology (ELISA) against different 351 SARS-CoV-2 Spike and Spike/RBD (Supplementary method).

352 4.3. Total immunoglobulin detection by Electrochemiluminescence assays

353 In order to confirm the serum status of each participant, total immunoglobulin reactivity of human 354 sera samples was tested against SARS-CoV-2 N and RBD at each sampling timepoint (V1, V2, V3) 355 using the Elecsys® electrochemiluminescence double-antigen sandwich assay performed on Cobas 356 e601. The Elecsys® anti-SARS-CoV-22Spike RBD is a quantitative immunoassay. According to the 357 manufacturer, a corrective factor (1.029) was applied to convert the results obtained in units per mL 358 to WHO International Standards for anti-SARS-CoV-2 antibodies in BAU/mL (Binding Arbitrary Units 359 per mL). For undiluted sera, SARS-CoV-2 RBD antibodies measuring range covered from 0.4 BAU/mL 360 to 257 BAU/mL and values higher than 0.8 BAU/mL were defined as positive. For sera whose values 361 were below the detection limits, automatized dilutions (1/100e and 1/10 000e) provided by the 362 supplier were used. The Elecsys® anti-SARS-CoV-2 Nucleocapsid assay provided a qualitative 363 detection of antibodies using a recombinant nucleocapsid protein. The result of SARS-CoV-2 N 364 antibodies was automatically computed in a cutoff index, with values ≥1.0 interpreted as reactive 365 corresponding to a positive result. Since these immunoassays were not available at the beginning of 366 the study, retrospective dosing on frozen serum aliquots (maximum thrice thawed) were performed. Independent serum samples were tested to confirm the lack of long-term effect of freezing (more 367 368 than 6 months) on the measuring results of these immunoassays (data not shown).

369 **4.4. Clinical samples selected for IgA detection**

A total of 400 volunteers achieved the totality of the longitudinal follow-up, including 249 individuals (62.3 %) remaining uninfected and 151 individuals (37.8 %) infected by SARS-CoV-2 (Supplementary Figure S1). For IgA detection in serum and saliva, we selected 75 naive individuals and 58 previouslyinfected individuals, based on the certainty of the diagnosis at enrollment (Table 1), including PCR and ELISA/ECLIA serology, the absence of a new COVID-19 infection during the longitudinal followup, and the quality/quantity of saliva samples (compliance to one-hour fasting before sampling, including non-smoking) (Supplementary figure S1).

377 4.5. Virus production

378 Vero cells (ATCC CCL-81) were grown in DMEM medium (Gibco Cat. No. 31966021, ThermoFisher 379 Scientific, Waltham, MA, USA). At confluence, the Vero cells were harvested and subsequently 380 seeded at 1.5×105 /mL in 96-well plates in order to reach confluence after 72 h at 37°C in 5% CO2. 381 Serial dilutions of stock viruses were made in the infection medium [DMEM supplemented with 50 382 U/mL penicillin, 50 mg/mL streptomycin (Gibco Cat. No. 15070063, ThermoFisher Scientific) and 383 TPCK-trypsin (Sigma Cat. No. T1426) at a final concentration of $1 \mu g/mL$]. For the neutralization test, 384 SARS-CoV-2 (BetaCoV/France/IDF0372/2020 strain) from clade 19A was isolated by the National 385 Reference Centre (CNR) for Respiratory Viruses (Institut Pasteur), as described previously (54). The 386 BetaCoV/France/IDF0372/2020 strain was supplied by CNR for Respiratory Viruses hosted by Institut 387 Pasteur, headed by Pr. Sylvie van der Werf. The human sample from which the 388 BetaCoV/France/IDF0372/2020 strain was isolated was provided by Dr. X. Lescure and Pr. Y. 389 Yazdanpanah from Bichat Hospital, Paris. Moreover, the BetaCoV/France/IDF0372/2020 strain was 390 supplied through the European Virus Archive goes Global (Evag) platform, a project that has received 391 funding from the European Union's Horizon 2020 research and innovation program under Grant No. 392 653316.

393 4.6. Virus titration

Briefly, 50 μL of 10-fold serial dilutions of SARS-CoV-2 were inoculated into eight replicate wells. The
96-well microplates were incubated at 37°C in a 5% CO2 atmosphere, and the cytopathic effect was
checked 5 days after inoculation. The virus titer was calculated according to the method of Reed and
Muench (55).

398 4.7. Seroneutralization assay

399 At each sampling timepoint (V1, V2, V3), the presence of neutralizing antibodies was sought by a 400 seroneutralization assay performed on Vero cells using the Institut Pasteur SARS-CoV-2 reference 401 BetaCoV/France/IDF0372/2020 strain, in a BSL3 facility. Neutralizing antibodies (Nab) tests were 402 performed in flat-bottomed microtitre plates (96 wells), 3 days after seeding the Vero cells. Two-fold 403 serial dilutions of inactivated sera, starting at a 1/40 dilution, were mixed with an equal volume of 404 SARS-CoV-2 (100 TCID50/50 μ L), and incubated for 1 h at 37°C. One hundred microlitres of the 405 serum-virus mixture and 100 µL of infection medium were inoculated in each well (four wells per 406 dilution), and the plates were incubated for 5 days at 37°C in 5% CO2. The cytopathic effect was 407 checked 5 days after inoculation. Neutralization titers were expressed as the inverse of the final 408 dilution of serum that neutralized 50% of the inoculated wells. As no cytopathic effects due to serum 409 cytotoxicity were observed at a dilution of 1/40, a neutralization titer of 40 was considered as 410 positive.

411 4.8. Quantification of serum and salivary IgA

412 At each sampling timepoint (V1, V2, V3), IgA reactivity of human serum and salivary samples was 413 quantified against SARS-CoV-2 Spike, Spike/RBD, Spike/NTD and Nucleocapsid, and the Spike of other 414 human coronaviruses (SARS-CoV-1, alpha HCOV-NL63, alpha HCOV-229E, beta HCOV-OC43 and beta 415 HCOV-HKU1) on a MesoQuickPlex SQ120 (Mesoscale discovery – MSD) using the V-PLEX COVID-19 416 Coronavirus Panel 2 IgA kit (MSD, K15371U) and according to the manufacturer's protocol. Briefly, 417 after a blocking step, wells from a 96-well plate were washed and incubated during 2 hours at 22°C 418 with diluted human serum samples (1: 5,000) or diluted human saliva samples (1:25). After three washing steps, bound antibodies were labelled with SULFO-TAGTM anti-human IgA antibody during 1 419 hour at 22°C. After three washing steps, read buffer was added and plates were read using MSD 420 421 QuickPlex SQ120 electrochemiluminescent detection system. Samples out of range were up diluted 422 and retested. Data were processed using MSD's Discovery Workbench version 4.0 and quantification 423 was reported in Arbitrary Units/mL (AU/mL) based on a reference standard curve included in the 424 assay. To assess assay precision and inter-assay variability, three serological controls, containing 425 known concentrations of human IgA against the panel targets', were run in duplicate on each plate.

The technical coefficient of variation (CV) of controls and the individual CV of negatives samples were calculated following the equation $\frac{\sigma}{m} \times 100$ (σ = standard deviation of calculated IgA-concentration, m = mean of calculated IgA-concentration). The positive threshold of each test was determined by

428 m – mean of calculated igA-concentration, the positive threshold of each test was determined by
 429 the quantitative variable maximizing both sensitivity and specificity (i.e. Youden index). The ROC
 430 curves are found in supplementary figure S2.

431 4.9. Statistical analysis

432 Statistical analyses were performed with R (version 4.2.5) using RStudio interface (version 433 2022.07.2+576). Graphical representations were made using ggplot2 package. Tests were performed 434 in a bilateral way and p-values under 0.05 were considered statistically significant. A correction for 435 multiple comparisons was applied using the Benjamini-Hochberg correction or Tukey HSD, resulting 436 in a corrected p-value (false discovery rate) at or under 0.05. Nevertheless, we used a false discovery 437 rate threshold of 0.2 for the association of persistent clinical symptoms with antigen-specific IgA 438 titers in order to avoid missing potential important association due to the weaker number of 439 subjects.

440 - Discrete independent variables and quantitative dependent:

Testing for group effect on a quantitative variable was performed with the following rank-based tests: Wilcoxon rank-sum test in unpaired two-group settings (comparing IgA concentration between naive and previously infected individuals); Kruskal-Wallis test with Dunn's correction when comparing multiple unpaired groups (or two-way ANOVA when homoscedasticity and normality of residual was assessed); Friedman test with Nemenyi post Hoc test when comparing multiple paired groups (e.g. comparing concentrations at several timings) using the PMCMR plus package.

447 - Quantitative variables:

448 Linear mixed models were used to describe time effect on quantitative variables (Imer function, Ime4 449 package). Following the Box Cox approach (powerTransform function, car package), concentrations 450 were log10 transformed in these linear models to maximize linearity, homoscedasticity and normality 451 of residuals. Simplification of complete models (free intercept and slope per individual for both time 452 and period effects) to allow the model to converge led to models with free intercept per individual 453 only. Slopes and intercepts were compared between conditions and periods using emmeans 454 package. 95 percent profile confidence intervals for model estimates were extracted using the 455 confint function, stats package.

- 456 5. Informed Consent Statement: All participants gave their written consent to the study. Ethical
 457 approval was given by the Committee for Protection of Persons engaged in clinical research (CPP
 458 20.05.25) and was registered in clinical trials.gov (NCT04408001).
- **6. Author Contributions:** Conceptualization, AT, JNT, DR; methodology, JD, AG, LC, AF, HT, FJ, CH, EBD, MM, AT; software, JD, AT, MM; statistical analysis, JD, AT, MM; resources, AT, MM; data curation, JD, AT; writing—original draft preparation, JD, AT, MM; writing—review and editing, JD, AT, MM, JNT, EBD, AFR; visualization, JD, MM, AT; supervision, MM, AT; All authors have read and agreed to the published version of the manuscript.
- 464 **7. Funding:** This work was supported by the Service de Santé des Armées, and the Agence Innovation
 465 Défense (projet ONADAP).

8. Acknowledgments: The authors thank the healthcare workers from HIA Percy who massively enrolled in the cohort and gave their time for clinical research during the difficult period of the initial wave of the COVID-19 outbreak. The authors also thank the Percy ImmunoCovid group volunteers that were not directly involved in this work but largely helped to manage the cohort (Nassima Airapetian, Cyril Badaut, Marie Baruteau, Marie De Laage, Amir Dib, Corinne Jamet, Quentin Laborde, 471 Carole Leclercq, Tiphaine Le Lièvre de la Morinière, Pierre-Yves Masse, Karine Michaud, Alice Nicolai, 472 Amandine Steiger), all the team of the department of laboratory medicine who performed 473 serological analysis (particularly Chrystelle Patole, Stéphanie Coppet, Pauline Chauvin) and PCR 474 testing, and all the nurses of HIA Percy (especially from the aeromedical center, the neurophysiology 475 and the anesthesia departments) who realized the blood samples. The authors are grateful to 476 Mesoscale Discovery[®] for a free of charge loan of a Meso QuickPlex SQ 120 and to Catherine Drogou 477 for her advice on saliva sample management. Finally, the authors address a special acknowledgment 478 to Dr Thépenier for the statistical analyses on R software, its precious help to manage the cohort and 479 for the critical revision of the manuscript.

9. Data availability: All data for this study are contained within the manuscript and the
 supplementary materials. The R script for running the analyses can be communicated on demand.

482 **10. Conflicts of Interest:** The authors declare no conflict of interest.

483 11. References

484 1. Kuster SP, Shah PS, Coleman BL, Lam PP, Tong A, Wormsbecker A, et al. Incidence of
485 influenza in healthy adults and healthcare workers: a systematic review and meta-analysis. PLoS One.
486 2011;6(10):e26239.

Vargese SS, Dev SS, Soman AS, Kurian N, Varghese VA, Mathew E. Exposure risk and COVIDinfection among frontline health-care workers: A single tertiary care centre experience. Clin
Epidemiol Glob Health. 2022;13:100933.

490 3. Hsu L, Wisplinghoff H, Kossow A, Hurrass J, Wiesmuller GA, Grune B, et al. Limited protection
491 against SARS-CoV-2 infection and virus transmission after mRNA vaccination. J Infect. 2022;84(1):94492 118.

493 4. Maugey N, Lefebvre T, Tournier JN, Neulat-Ripoll F, Chapus C, Grandperret V, et al. Vaccine
494 efficacy against the SARS-CoV-2 Delta variant during a COVID-19 outbreak aboard a military ship. BMJ
495 Mil Health. 2022.

496 5. Mura M, Simon F, Pommier de Santi V, Tangy F, Tournier JN. Role and Limits of COVID-19
497 Vaccines in the Delicate Transition from Pandemic Mitigation to Endemic Control. Vaccines (Basel).
498 2022;10(9).

499 6. Puhach O, Meyer B, Eckerle I. SARS-CoV-2 viral load and shedding kinetics. Nat Rev Microbiol.
500 2022.

501 7. Langel SN, Johnson S, Martinez CI, Tedjakusuma SN, Peinovich N, Dora EG, et al. Adenovirus
 502 type 5 SARS-CoV-2 vaccines delivered orally or intranasally reduced disease severity and transmission
 503 in a hamster model. Sci Transl Med. 2022;14(658):eabn6868.

5048.Lapuente D, Fuchs J, Willar J, Vieira Antao A, Eberlein V, Uhlig N, et al. Protective mucosal505immunity against SARS-CoV-2 after heterologous systemic prime-mucosal boost immunization. Nat506Commun. 2021;12(1):6871.

Mao T, Israelow B, Pena-Hernandez MA, Suberi A, Zhou L, Luyten S, et al. Unadjuvanted
intranasal spike vaccine elicits protective mucosal immunity against sarbecoviruses. Science.
2022;378(6622):eabo2523.

510 10. Yaugel-Novoa M, Bourlet T, Paul S. Role of the humoral immune response during COVID-19:
511 guilty or not guilty? Mucosal Immunol. 2022.

512 11. Smith N, Goncalves P, Charbit B, Grzelak L, Beretta M, Planchais C, et al. Distinct systemic and 513 mucosal immune responses during acute SARS-CoV-2 infection. Nat Immunol. 2021;22(11):1428-39.

514 12. Brandtzaeg P. Secretory immunity with special reference to the oral cavity. J Oral Microbiol.515 2013;5.

516 13. Bunker JJ, Erickson SA, Flynn TM, Henry C, Koval JC, Meisel M, et al. Natural polyreactive IgA 517 antibodies coat the intestinal microbiota. Science. 2017;358(6361).

518 14. Huang N, Perez P, Kato T, Mikami Y, Okuda K, Gilmore RC, et al. SARS-CoV-2 infection of the 519 oral cavity and saliva. Nat Med. 2021;27(5):892-903.

520 15. Isho B, Abe KT, Zuo M, Jamal AJ, Rathod B, Wang JH, et al. Persistence of serum and saliva 521 antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients. Sci Immunol. 2020;5(52).

522 16. Sheikh-Mohamed S, Isho B, Chao GYC, Zuo M, Cohen C, Lustig Y, et al. Systemic and mucosal
523 IgA responses are variably induced in response to SARS-CoV-2 mRNA vaccination and are associated
524 with protection against subsequent infection. Mucosal Immunol. 2022;15(5):799-808.

For the second second

528 18. Spinicci M, Graziani L, Tilli M, Nkurunziza J, Vellere I, Borchi B, et al. Infection with SARS-CoV529 2 Variants Is Associated with Different Long COVID Phenotypes. Viruses. 2022;14(11).

530 19. Butowt R, Bilinska K, von Bartheld CS. Olfactory dysfunction in COVID-19: new insights into 531 the underlying mechanisms. Trends Neurosci. 2022.

Mendes Paranhos AC, Nazareth Dias AR, Machado da Silva LC, Vieira Hennemann Koury G, de
Jesus Sousa E, Cerasi AJ, Jr., et al. Sociodemographic Characteristics and Comorbidities of Patients
With Long COVID and Persistent Olfactory Dysfunction. JAMA Netw Open. 2022;5(9):e2230637.

535 21. McWilliams MP, Coelho DH, Reiter ER, Costanzo RM. Recovery from Covid-19 smell loss:
536 Two-years of follow up. Am J Otolaryngol. 2022;43(5):103607.

537 22. Klein J, Wood J, Jaycox J, Lu P, Dhodapkar RM, Gehlhausen JR, et al. Distinguishing features of 538 Long COVID identified through immune profiling. medRxiv. 2022.

Peghin M, De Martino M, Palese A, Gerussi V, Bontempo G, Graziano E, et al. Post-COVID-19
syndrome and humoral response association after 1 year in vaccinated and unvaccinated patients.
Clin Microbiol Infect. 2022;28(8):1140-8.

542 24. Saussez S, Sharma S, Thiriard A, Olislagers V, Vu Duc I, Le Bon SD, et al. Predictive factors of
543 smell recovery in a clinical series of 288 coronavirus disease 2019 patients with olfactory dysfunction.
544 Eur J Neurol. 2021;28(11):3702-11.

545 25. Sano K, Bhavsar D, Singh G, Floda D, Srivastava K, Gleason C, et al. SARS-CoV-2 vaccination 546 induces mucosal antibody responses in previously infected individuals. Nat Commun. 547 2022;13(1):5135.

S48 26. Russell MW, Moldoveanu Z, Ogra PL, Mestecky J. Mucosal Immunity in COVID-19: A
S49 Neglected but Critical Aspect of SARS-CoV-2 Infection. Front Immunol. 2020;11:611337.

550 27. Guerra ENS, de Castro VT, Amorim Dos Santos J, Acevedo AC, Chardin H. Saliva is suitable for
 551 SARS-CoV-2 antibodies detection after vaccination: A rapid systematic review. Front Immunol.
 552 2022;13:1006040.

Hettegger P, Huber J, Passecker K, Soldo R, Kegler U, Nohammer C, et al. High similarity of
IgG antibody profiles in blood and saliva opens opportunities for saliva based serology. PLoS One.
2019;14(6):e0218456.

Seneviratne CJ, Balan P, de Alwis R, Udawatte NS, Herath T, Toh JZN, et al. BNT162b2 mRNA
Vaccine-Induced Immune Response in Oral Fluids and Serum. Int Dent J. 2022.

30. Tada A, Senpuku H. The Impact of Oral Health on Respiratory Viral Infection. Dent J (Basel).
2021;9(4).

56031.Tsunetsugu-Yokota Y, Ito S, Adachi Y, Onodera T, Kageyama T, Takahashi Y. Saliva as a useful561tool for evaluating upper mucosal antibody response to influenza. PLoS One. 2022;17(2):e0263419.

32. Moldoveanu Z, Clements ML, Prince SJ, Murphy BR, Mestecky J. Human immune responses
to influenza virus vaccines administered by systemic or mucosal routes. Vaccine. 1995;13(11):100612.

565 33. Dan JM, Mateus J, Kato Y, Hastie KM, Yu ED, Faliti CE, et al. Immunological memory to SARS-566 CoV-2 assessed for up to 8 months after infection. Science. 2021;371(6529).

S67 34. Chansaenroj J, Yorsaeng R, Puenpa J, Wanlapakorn N, Chirathaworn C, Sudhinaraset N, et al.
S68 Long-term persistence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike
S69 protein-specific and neutralizing antibodies in recovered COVID-19 patients. PLoS One.
S70 2022;17(4):e0267102.

571 35. Shi D, Weng T, Wu J, Dai C, Luo R, Chen K, et al. Dynamic Characteristic Analysis of Antibodies 572 in Patients With COVID-19: A 13-Month Study. Front Immunol. 2021;12:708184.

573 36. Sterlin D, Mathian A, Miyara M, Mohr A, Anna F, Claer L, et al. IgA dominates the early 574 neutralizing antibody response to SARS-CoV-2. Sci Transl Med. 2021;13(577).

57537.Wang J, Deng C, Liu M, Liu Y, Li L, Huang Z, et al. A fourth dose of the inactivated SARS-CoV-2576vaccine redistributes humoral immunity to the N-terminal domain. Nat Commun. 2022;13(1):6866.

57738.McCallum M, De Marco A, Lempp FA, Tortorici MA, Pinto D, Walls AC, et al. N-terminal578domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2. Cell. 2021;184(9):2332-47579e16.

S80 39. Carsetti R, Zaffina S, Piano Mortari E, Terreri S, Corrente F, Capponi C, et al. Different Innate
and Adaptive Immune Responses to SARS-CoV-2 Infection of Asymptomatic, Mild, and Severe Cases.
Front Immunol. 2020;11:610300.

583 40. Cervia C, Nilsson J, Zurbuchen Y, Valaperti A, Schreiner J, Wolfensberger A, et al. Systemic 584 and mucosal antibody responses specific to SARS-CoV-2 during mild versus severe COVID-19. J 585 Allergy Clin Immunol. 2021;147(2):545-57 e9.

41. Wang Z, Lorenzi JCC, Muecksch F, Finkin S, Viant C, Gaebler C, et al. Enhanced SARS-CoV-2
neutralization by dimeric IgA. Sci Transl Med. 2021;13(577).

42. Becker M, Strengert M, Junker D, Kaiser PD, Kerrinnes T, Traenkle B, et al. Exploring beyond clinical routine SARS-CoV-2 serology using MultiCoV-Ab to evaluate endemic coronavirus crossreactivity. Nat Commun. 2021;12(1):1152.

43. Narowski TM, Raphel K, Adams LE, Huang J, Vielot NA, Jadi R, et al. SARS-CoV-2 mRNA
vaccine induces robust specific and cross-reactive IgG and unequal neutralizing antibodies in naive
and previously infected people. Cell Rep. 2022;38(5):110336.

59444.Azzi L, Dalla Gasperina D, Veronesi G, Shallak M, letto G, Iovino D, et al. Mucosal immune595response in BNT162b2 COVID-19 vaccine recipients. EBioMedicine. 2022;75:103788.

596 45. Chivu-Economescu M, Bleotu C, Grancea C, Chiriac D, Botezatu A, Iancu IV, et al. Kinetics and 597 persistence of cellular and humoral immune responses to SARS-CoV-2 vaccine in healthcare workers 598 with or without prior COVID-19. J Cell Mol Med. 2022;26(4):1293-305.

59946.Zurac S, Nichita L, Mateescu B, Mogodici C, Bastian A, Popp C, et al. COVID19 vaccination and600IgG and IgA antibody dynamics in healthcare workers. Mol Med Rep. 2021;24(2).

Garziano M, Utyro O, Poliseno M, Santantonio TA, Saulle I, Strizzi S, et al. Natural SARS-CoV-2
Infection Affects Neutralizing Activity in Saliva of Vaccinees. Front Immunol. 2022;13:820250.

603 48. Knight M, Changrob S, Li L, Wilson PC. Imprinting, immunodominance, and other 604 impediments to generating broad influenza immunity. Immunol Rev. 2020;296(1):191-204.

49. McCarthy KR, Von Holle TA, Sutherland LL, Oguin TH, 3rd, Sempowski GD, Harrison SC, et al.
Differential immune imprinting by influenza virus vaccination and infection in nonhuman primates.
Proc Natl Acad Sci U S A. 2021;118(23).

60850.Otte MS, Klussmann JP, Luers JC. Persisting olfactory dysfunction in patients after recovering609from COVID-19. J Infect. 2020;81(3):e58.

610 51. de Melo GD, Lazarini F, Levallois S, Hautefort C, Michel V, Larrous F, et al. COVID-19-related 611 anosmia is associated with viral persistence and inflammation in human olfactory epithelium and 612 brain infection in hamsters. Sci Transl Med. 2021;13(596).

52. Rank A, Tzortzini A, Kling E, Schmid C, Claus R, Loll E, et al. One Year after Mild COVID-19: The
Majority of Patients Maintain Specific Immunity, But One in Four Still Suffer from Long-Term
Symptoms. J Clin Med. 2021;10(15).

53. Schambeck SE, Mateyka LM, Burrell T, Graf N, Brill I, Stark T, et al. Two-Year Follow-Up on
617 Chemosensory Dysfunction and Adaptive Immune Response after Infection with SARS-CoV-2 in a
618 Cohort of 44 Healthcare Workers. Life (Basel). 2022;12(10).

54. Lescure FX, Bouadma L, Nguyen D, Parisey M, Wicky PH, Behillil S, et al. Clinical and
virological data of the first cases of COVID-19 in Europe: a case series. Lancet Infect Dis.
2020;20(6):697-706.

- 622 55. Reed LJ, Muench H. A simple method of estimating fifty percent endpoints. Am J Epidemiol.
- 623 1938;27:493-7.

625 <u>Table 1:</u> Main characteristics of naive individuals (COVID-) and previously infected individuals

626 (COVID+) at the initial visit (V1).

627

		COVID+	COVID-
Gender and age	Total of individuals: N	58	75
	Women: N (%)	39 (67.2%)	54 (72%)
	Men: N (%)	19 (32.8%)	21 (28%)
	Age in years: median [IQR] (range)	35.5 [29-46.5] (20-61)	41 [34.5-46.5] (22-69)
COVID-19 diagnosis	PCR+ confirmed: N (%)	36 (62.1%)	0 (0%)
	RBD and Spike positive serologies by ELISA: N (%)	44 (75.9%)	0 (0%)
	Nucleocapsid positive serology by ECLIA: N (%)	56 (96.6%)	0 (0%)
	RBD positive serology by ECLIA: N (%)	55 (94.8%)	0 (0%)
Presence of symptoms at the initial visit (V1)	Asymptomatic: N (%)	2 (3.4%)	Not concerned
	Symptomatic: N (%)	56 (96.6%)	Not concerned
	Days post-onset of symptoms at V1: median [IQR] (range)	45 [39-61] (8-118)	Not concerned

629 <u>Table 2:</u> Vaccination status of naive individuals (COVID-) and previously infected individuals (COVID+)

630 at the last visit (V3).

		COVID+	COVID-
Participants at visit three (V3)	Total of individuals: N	58	75
	N (% of total individuals)	29 (50%)	18 (24%)
	Women: N (%)	20 (69%)	14(77.8%)
No vaccine	Men: N (%)	9 (31%)	4 (22.2%)
	Age in years: median [IQR] (range)	37 [28-47] (20-61)	37.5 [31.8-42.5] (22-61)
	N (% of total individuals)	20 (34.5%)	15 (20%)
	Women: N (%)	14 (70%)	12 (80%)
	Men: N (%)	6 (30%)	3 (20%)
One vaccine dose	Age in years: median [IQR] (range)	34 [29-38.5] (26-55)	42 [34.5-44] (22-47)
	Days post first vaccine at V3: median [IQR] (range)	71 [47-98] (10-148)	93[68-115] (9-140)
	N (% of total individuals)	9 (15.5%)	42 (56%)
	Women: N (%)	5 (55.6%)	28 (66.7%)
	Men: N (%)	4 (44.4%)	14 (33.3%)
Two vaccine doses	Age in years: median [IQR] (range)	41 [32-58] (26-59)	43 [37.3-48.8] (22-69)
	Days post second vaccine at V3: median [IQR] (range)	86 [19-104] (7-120)	57 [28-92] (1-113)
	Interval (in days) between 2 doses: median [IQR] (range)	28 [28-74] (21-84)	28 [28-47.8] (21-93)

632 Table 3: Vaccine schedule of naive (COVID-) and previously infected individuals (COVID+) at the last visit (V3).

633

Vaccine schedule		COVID+	COVID-
	N (%)	13 (22.4%)	4 (5.3%)
	Women: N (%)	8 (61.5%)	3 (75%)
One dose: Pfizer	Men: N (%)	5 (38.5%)	1 (25%)
	Age in years: median [IQR] (range)	35 [29-38] (25-55)	43.5 [38-44.3] (23-45)
	Days post first dose: median [IQR] (range)	47 [21- 62] (10-111)	29 [19.5- 44.5] (9-73)
	N (%)	7 (12.1%)	11 (14.7%)
	Women: N (%)	6 (85.7%)	9 (81.8%)
One dose:	Men: N (%)	1 (14.3%)	2(18.2%)
Astrazeneta	Age in years: median [IQR] (range)	33 [30- 38.5] (28-43)	42 [34.5- 43] (22-47)
	Days post first dose: median [IQR] (range)	60 [56.5-71] (42-80)	77 [67.5-81] (61-90)
	N (%)	6 (10.3%)	31 (41.3%)
	Women: N (%)	3 (50%)	18 (58.1%)
Two doses	Men: N (%)	3 (50%)	13 (41.9%)
Pfizer/Pfizer	Age in years: median [IQR] (range)	54.5 [36.8-58] (28-59)	45 [40-50.5] (22-69)
	Days post second dose: median [IQR] (range)	98 [87.5-106.3] (77-120)	87 [44-95.5] (1-113)
	Interval (in days) between 2 doses: median [IQR] (range)	28 [27.3-28] (21-28)	28 [27-28] (21-49)
	N (%)	3 (5.2%)	11 (14.7%)
	Women: N (%)	2 (66.7%)	10 (90.9%)
Two doses:	Men: N (%)	1 (33.3%)	1 (9.1%)
straZeneca/Pfizer	Age in years: median [IQR] (range)	36 [31-38.5] (26-41)	36 [29-38] (28-58)
	Days post second dose: median [IQR] (range)	13 [10-16] (7-19)	19 [6-28] (1-63)
	Interval (in days) between 2 doses: median [IQR] (range)	79 [76.5-81.5] (74-84)	77 [68-81] (35-93)



636





Figure 1: Serum anti-SARS-COV-2 IgA kinetics and specificity up to 16 months after COVID-19 acute infection and without immunization. Serology titers of anti-SARS-CoV2 IgA (UA/ml) from naive (COVID-, blue) and previously infected (COVID+, red) individuals at V1, and its kinetic of decrease (mean slope in red) for symptomatic COVID-19+ individuals up to 16 months after the acute infection. (A) Serology IgA titers against the whole Spike. (B) Serology IgA titers against the Spike/RBD. (C) Serology IgA titers against the Spike/NTD. (D) Serology IgA titers against the

644 Nucleocapsid. The red dashed line corresponded to the positivity threshold.

645 Wilcoxon-rank sum test: ns = not significant, *** p<0.001. Linear mixed models were used to 646 calculate the mean slope between each visit (red line).



649





Figure 2: Serum anti-SARS-CoV-2 total Immunoglobulins (Ig) and seroneutralization titers at each visit and without immunization for previously infected individuals. (A) Titers of total Ig targeting the Spike/RBD and (B) the Nucleocapsid in serum from previously infected individuals are represented at enrollment (V1), 6 months (V2) and 12 months (V3) later. (C) Seroneutralization titers from previously infected individuals at V1, V2 and V3.

656 The positivity thresholds are represented with a red dashed line. Linear regression slopes from (A)

- and (B) were significantly different from zero with p < 0.001.
- 658



660



661

Figure 3: Saliva anti-SARS-CoV-2 IgA kinetics and specificity up to 16 months after COVID-19 acute infection and without immunization. Salivary titers of anti-SARS-CoV2 IgA (UA/mI) from naive (COVID-, blue) and previously infected (COVID+, red) individuals at enrollment (V1), and its kinetic of decrease (mean slope in red) for symptomatic infected individuals up to 16 months after the acute infection. (A) Salivary IgA titers against the whole Spike. (B) Salivary IgA titers against the Spike/RBD. (C) Salivary IgA titers against the Spike/NTD. (D) Salivary IgA titers against the Nucleocapsid.

668 Wilcoxon-rank sum test: ns = not significant, ** p<0.01, *** p<0.001. Linear mixed models were used

- to calculate the mean slope between each visit (red line).
- 670







673

674 Figure 4: Serum and saliva anti-Spike IgA titers against human coronaviruses. (A) Normalized log-10 675 transformed serology titers of anti-Spike IgA (log10 UA/ml) in saliva (left) and serum (right) from 676 naive (COVID-, blue) and previously infected (COVID+, red) individuals measured by MSD technology 677 at enrollment (V1). IgA specificity corresponds to the Spike proteins from human coronaviruses 678 (hCoV) 229E, HKU1, NL63, OC43, SARS-CoV-1 and SARS-CoV-2. Kruskal-Wallis test: ns=not significant; 679 * p<0.05 ; *** p<0.001. (B) Correlation matrices in saliva (left) and serum (right) at V1 showing 680 significant positive correlations between alpha-coronaviruses (hCoV 229E and NL63), betacoronaviruses (hCoV OC43, HKU1, SARS-CoV-1, SARS-CoV-2), as well as SARS-CoV-2 antigen 681 682 specificity (N, Spike, Spike/RBD, Spike/NTD) in previously infected individuals. Only significant 683 correlations (Spearman, p<0.05) are represented on the matrices. The color and size of the dots 684 (scale next to the graph) indicate the degree of correlation (Spearman, rho) between the different 685 parameters (small to large indicating low to high correlation).



689

Figure 5: Impact of the number of vaccine doses on serum anti-SARS-CoV-2 IgA titers in the presence (red) or absence (blue) of a previous COVID-19 infection. (A) Serology IgA titers against the whole Spike. (B) Serology IgA titers against the Spike/RBD. (C) Serology IgA titers against the Spike/NTD. (D) Serology IgA titers against the Nucleocapsid.

Two-Way ANOVA tests with Tukey post'hoc test: ns = not significant; * p<0.05 ; ** p<0.001; *** p<0.001.







699

Figure 6: Impact of the number of vaccine doses on saliva anti-SARS-CoV-2 IgA titers in the presence (red) or absence (blue) of a previous COVID-19 infection. (A) Salivary IgA titers against the whole Spike. (B) Salivary IgA titers against the Spike/RBD. (C) Salivary IgA titers against the Spike/NTD. (D) Salivary IgA titers against the Nucleocapsid.

Two-Way ANOVA tests with Tukey post'hoc test: ns = not significant; * p<0.05 ; ** p<0.001; ***
 p<0.001.



708 Figure 7: SARS-CoV-2 vaccination reactivated mucosal immunity in previously infected individuals. 709 710 (A) Salivary anti-Spike IgA post-immunization (Visit 3) positively correlated with salivary anti-Spike IgA post-infection (Visit 1) in previously infected individuals (Pearson correlation, R^2 =0.735, p<0.001). (B) 711 After immunization, the correlation between saliva and serum anti-Spike IgA was well differentiated 712 713 in naive (COVID-, blue) and previously infected (COVID+, red) individuals, underlining the reactivation 714 of mucosal immunity in previously infected individuals only: COVID+ group (Adj R2=0.44, slope = 715 0.45) ; COVID- group (Adj R2=0.31, slope = 1), p<0.001. 716

717 Figure 8

718

A. TASTE DISORDERS



719

Figure 8: Persistent taste and smell disorders more than one year after infection are associated 720 721 with higher initial titers of anti-Spike NTD IgA. (A) Normalized log-10 transformed serology titers of 722 anti-SARS-CoV-2 IgA (log10 UA/ml) in saliva (left) and serum (right) measured at visit 1 by MSD 723 technology from individuals suffering from taste disorders persistent for less (brown, n=28) or more 724 (orange, n=10) than one year. (B) Normalized log-10 transformed serology titers of anti-SARS-CoV-2 725 IgA (log10 UA/ml) in saliva (left) and serum (right) measured at visit 1 by MSD technology from 726 individuals suffering from smell disorders persistent for less (brown, n=27) or more (orange, n=15) 727 than one year.

728 Antigen specificity corresponds to the Nucleocapsid (N), Spike (S), Spike-receptor binding domain

729 (S_RBD) and Spike-N-terminal domain (S_NTD).

730 Kruskal-Wallis test: ns=not significant; * p<0.05.



















A. TASTE DISORDERS



B. SMELL DISORDERS

